Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.creator | Camargo, Elaine Aparecida de | - |
Autor(es): dc.creator | Silva, Glenda Nicioli da | - |
Autor(es): dc.creator | Gobette, Camila Pereira | - |
Autor(es): dc.creator | Marcondes, João Paulo de Castro | - |
Autor(es): dc.creator | Salvadori, Daisy Maria Fávero | - |
Data de aceite: dc.date.accessioned | 2019-11-06T13:34:48Z | - |
Data de disponibilização: dc.date.available | 2019-11-06T13:34:48Z | - |
Data de envio: dc.date.issued | 2015-05-26 | - |
Data de envio: dc.date.issued | 2015-05-26 | - |
Data de envio: dc.date.issued | 2013 | - |
Fonte completa do material: dc.identifier | http://www.repositorio.ufop.br/handle/123456789/5534 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/capes/558580 | - |
Descrição: dc.description | Tumor response to antineoplastic drugs is not always predictable. This is also true for bladder carcinoma, a highly recurrent neoplasia. Currently, the combination of cisplatin and gemcitabine is well accepted as a standard protocol for treating bladder carcinoma. However, in some cases, this treatment protocol causes harmful side effects. Therefore, we investigated the roles of the genes TP53, RASSF1A (a tumor suppressor gene) and hMLH1 (a gene involved in the mismatch repair pathway) in cell susceptibility to cisplatin/gemcitabine treatment. Two bladder transitional carcinoma cell (TCC) lines, RT4 (wild-type TP53) and 5637 (mutated TP53), were used in this study. First, we evaluated whether the genotoxic potential of cisplatin/gemcitabine was dependent on TP53 status. Then, we evaluated whether the two antineoplastic drugs modulated RASSF1A and hMLH1 expression in the two cell lines. Increased DNA damage was observed in both cell lines after treatment with cisplatin or gemcitabine and with the two drugs simultaneously, as depicted by the comet assay. A lack of RASSF1A expression and hypermethylation of its promoter were observed before and after treatment in both cell lines. On the other hand, hMLH1 downregulation, unrelated to methylation status, was observed in RT4 cells after treatment with cisplatin or with cisplatin and gemcitabine simultaneously (wild-type TP53); in 5637 cells, hMLH1 was upregulated only after treatment with gemcitabine. In conclusion, the three treatment protocols were genotoxic, independent of TP53 status. However, cisplatin was the most effective, causing the highest level of DNA damage in both wild-type and mutated TP53 cells. Gemcitabine was the least genotoxic agent in both cell lines. Furthermore, no relationship was observed between the amount of DNA damage and the level of hMLH1 and RASSF1A expression. Therefore, other alternative pathways might be involved in cisplatin and gemcitabine genotoxicity in these two bladder cancer cell lines. | - |
Idioma: dc.language | en | - |
Direitos: dc.rights | Papers published by APJCP are published and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/ licenses/by/3.0/), under which authors reserve the copyright for their content; however, they permit anyone unrestricted non-commercial use as long as the original authors and source are cited. Fonte: APJCP <http://www.apocpcontrol.org/page/information.php>. Acesso em: 22 mai. 2015. | - |
Palavras-chave: dc.subject | Gene expression profile | - |
Palavras-chave: dc.subject | Genotoxicity | - |
Título: dc.title | No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine. | - |
Aparece nas coleções: | Repositório Institucional - UFOP |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: